2.02
0.98%
-0.02
Oragenics Inc 주식(OGEN)의 최신 뉴스
Closing Bell Recap: Oragenics Inc (OGEN) Ends at 2.04, Reflecting a 3.55 Upturn – DWinneX - The Dwinnex
The Dwinnex
Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com - Defense World
Defense World
Ratio Examination: Oragenics Inc (OGEN)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
The Dwinnex
Oragenics names new Chief Clinical Officer By Investing.com - Investing.com Canada
Investing.com Canada
Oragenics Appoints William “Frank” Peacock MD As Chief Clinical Officer - citybiz
citybiz
Oragenics names new Chief Clinical Officer By Investing.com - Investing.com Australia
Investing.com Australia
Oragenics names new Chief Clinical Officer By Investing.com - Investing.com
Investing.com
Oragenics names new Chief Clinical Officer By Investing.com - Investing.com UK
Investing.com UK
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer - GlobeNewswire
GlobeNewswire
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer - Yahoo Finance
Yahoo Finance
Holdings of Oragenics Inc (OGEN) are aligned with the stars – Sete News - SETE News
SETE News
ImmunityBio (NASDAQ: IBRX) Advances in Oncology: Gearing Up for ANKTIVA's Commercial Rollout - BP Journal
BP Journal
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
Defense World
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
Defense World
Oragenics prepares ONP-002 for Phase II concussion trial - TipRanks.com - TipRanks
TipRanks
Oragenics, Inc (NYSE: OGEN) Surges 34% Amidst Webinar Announcement and Intranasal Pharmaceutical Development - BP Journal
BP Journal
Nuburu Inc (NYSE: BURU) Surges Amid Exciting Developments - BP Journal
BP Journal
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - GlobeNewswire
GlobeNewswire
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - Markets Insider
Markets Insider
Oragenics climbs 9% amid Phase 2 study, business updates - MSN
MSN
Oragenics climbs 9% amid Phase 2 study, business updates (NYSE:OGEN) - Seeking Alpha
Seeking Alpha
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial - GlobeNewswire
GlobeNewswire
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial - Markets Insider
Markets Insider
Oragenics climbs 9% amid Phase 2 study, business updates (NYSE:OGEN) - Seeking Alpha
Seeking Alpha
Oragenics: Q1 Earnings Snapshot | Business | valdostadailytimes.com - Valdosta Daily Times
Valdosta Daily Times
Oragenics: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference - The Globe and Mail
The Globe and Mail
Oragenics, Inc. Announces New Chair - The Globe and Mail
The Globe and Mail
SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice - The Globe and Mail
The Globe and Mail
Oragenics, Inc. Announces $6.5 Million Registered Direct Offering - The Globe and Mail
The Globe and Mail
Oragenics to Participate in the World Vaccine Congress Washington - The Globe and Mail
The Globe and Mail
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine - The Globe and Mail
The Globe and Mail
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
Defense World
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia - Markets Insider
Markets Insider
Oragenics Inc Reports SEC Filing Update - TipRanks.com - TipRanks
TipRanks
Oragenics partners with Avance Clinical for Phase 2 concussion study (NYSE:OGEN) - Seeking Alpha
Seeking Alpha
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia - GlobeNewswire
GlobeNewswire
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia - GlobeNewswire
GlobeNewswire
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
Defense World
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
Defense World
Sarasota biotech company noncompliant with NYSE listing standards - Business Observer
Business Observer
Oragenics advances with new neurological treatment platform - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
Oragenics Announces Closing of Public Offering - Business Wire
Business Wire
S&P 500 Edges Lower; ADT Posts Upbeat Earnings
Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
Benzinga
Dow Dips 200 Points; TJX Posts Upbeat Sales
Benzinga
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
Benzinga
Oragenics Inc Announces Proposed Public Stock Offering - TipRanks.com - TipRanks
TipRanks
Oragenics Shares Tumble Premarket After Stock Offering - MarketWatch
MarketWatch
자본화:
|
볼륨(24시간):